Mucinoses

Global Scleroderma Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 21, 2021
Health, Clinical trials, Health sciences, Health, Life sciences, Drug discovery, Clinical research, Pharmaceutical industry, Autoimmune diseases, Mucinoses, Scleroderma, Clinical trial, Systemic scleroderma

The "Global Scleroderma Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Scleroderma Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Scleroderma Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Scleroderma market.
  • It covers emerging therapies for Scleroderma in active clinical development stages including early and late stage clinical trials.
  • The report provides Scleroderma pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Philip J. Clements, MD, MPH, MACR, is recognized by Continental Who's Who

Retrieved on: 
Friday, June 11, 2021
Medical specialties, Autoimmune diseases, Clinical medicine, Medicine, Rheumatology, Mucinoses, Syndromes, Rare diseases, Raynaud syndrome, Scleroderma, David Geffen School of Medicine at UCLA

For nearly 50 years, he has garnered a well-deserved reputation for his vast repertoire of expertise and professional experience.

Key Points: 
  • For nearly 50 years, he has garnered a well-deserved reputation for his vast repertoire of expertise and professional experience.
  • He is devoted to educating future medical professionals as an Emeritus Professor of Medicine for the David Geffen School of Medicine at UCLA.
  • As a Rheumatologist, he has been a key opinion leader in Scleroderma and Raynaud's disease and has conducted many clinical trials.
  • He would also like to recognize his beautiful family his wife of 35 years, Ellie, and his children, Philip Jr, Annette, and David.

Systemic Sclerosis (Scleroderma) Epidemiology Forecast to 2030: Focus on US, France, Germany, Italy, Spain, UK, and Japan - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 10, 2021
Biotechnology, Pharmaceutical, Health, Organ systems, Autoimmune diseases, Mucinoses, Medicine, Anatomy, Rare diseases, Systemic scleroderma, Scleroderma, Sclerosis

The "Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Systemic Sclerosis (Scleroderma) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of SSc.
  • Women accounted for more diagnosed prevalent cases of SSc than men in the 7MM and it predominantly affects older adults.
  • The report includes a 10-year epidemiological forecast for the diagnosed prevalent cases of SSc segmented by sex and age (ages 18 years).

Scleroderma Foundation Announces New CEO

Retrieved on: 
Wednesday, May 26, 2021
Boletales, Mucinoses, Autoimmune diseases, Scleroderma, Medical specialties, Clinical medicine, Medicine

DANVERS, Mass., May 26, 2021 /PRNewswire/ -- The Scleroderma Foundation is pleased to announce the hiring of Mary J. Wheatley, IOM, CAE as CEO of the foundation, effective July 1, 2021.

Key Points: 
  • DANVERS, Mass., May 26, 2021 /PRNewswire/ -- The Scleroderma Foundation is pleased to announce the hiring of Mary J. Wheatley, IOM, CAE as CEO of the foundation, effective July 1, 2021.
  • Riggs guided the organization through the merger of the United Scleroderma Foundation and the Scleroderma Federation, and recently led development of a strategic plan to enhance fundraising capabilities and to realign organizational management.
  • "This is an exciting time for the Scleroderma Foundation," said Cos Mallozzi, chair of the foundation's national board of directors.
  • The Scleroderma Foundation is dedicated to serving the needs of the scleroderma community through its three-fold mission: support, education, and research.

Global Scleroderma Epidemiology and Patient Flow Report 2021: Identify Patients Segments Through Age Groups, Gender, and Disease Sub-Types - ResearchAndMarkets.com

Retrieved on: 
Friday, May 7, 2021
Health, General Health, Autoimmune diseases, Medical specialties, Organ systems, Mucinoses, Clinical medicine, Scleroderma, Connective tissue diseases, Rheumatology, Systemic scleroderma, Scleromyositis

b'The "Global Scleroderma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Scleroderma Epidemiology and Patient Flow Analysis - 2021, provides Scleroderma epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Scleroderma Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Scleroderma Epidemiology and Patient Flow Analysis - 2021, provides Scleroderma epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Scleroderma patients, history of the disease at the population level (Scleroderma prevalence, Scleroderma incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Scleroderma patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Scleroderma market sizing, assessing market potential, and developing drug forecast models\nIdentify Scleroderma patients segments through age groups, gender, and disease sub-types\n'

Emerald Health Pharmaceuticals Starts Activities for Initiation of Phase 2 Clinical Study in Multiple Sclerosis

Retrieved on: 
Monday, March 8, 2021
Medical specialties, Autoimmune diseases, Organ systems, Mucinoses, Clinical medicine, Rare diseases, Immunology, Systemic scleroderma, EHP, Scleroderma, Autoimmunity

The initiation of this MS Phase 2 study is another important milestone for our lead product candidate, EHP-101, saidJoachim Schupp, M.D., Dr.

Key Points: 
  • The initiation of this MS Phase 2 study is another important milestone for our lead product candidate, EHP-101, saidJoachim Schupp, M.D., Dr.
  • Jim DeMesa, M.D., M.B.A., EHPs President and CEO added, This MS clinical study is the second Phase 2 study we are conducting with EHP-101.
  • About Emerald Health Pharmaceuticals Inc.
    Emerald Health Pharmaceuticals is developing proprietary product candidates to treat CNS, autoimmune, and other diseases.
  • EHP-101 is in Phase 2 clinical development for the treatment of systemic sclerosis, a severe form of scleroderma, and multiple sclerosis.

Insights on the Systemic Scleroderma Treatment Global Market to 2028 - Featuring Roche, United Therapeutics & Boehringer Ingelheim International Among Others

Retrieved on: 
Monday, March 1, 2021
Autoimmune diseases, Organ systems, Medical specialties, Mucinoses, Anatomy, Connective tissue diseases, Systemic scleroderma, Scleroderma, Systemic, Calcium channel blocker

Global Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)

Key Points: 
  • Global Systemic Scleroderma Treatment Market, By Drug Class, 2016-2028 (USD Million)
    5.3.1.
  • Global Systemic Scleroderma Treatment Market, by Immuno-suppressors, By Region, 2016-2028 (USD Million)
    5.4.1.
  • Global Systemic Scleroderma Treatment Market, by Phosphodiesterase 5 inhibitors-PHA, by Region, 2016-2028 (USD Million)
    5.5.1.
  • Global Systemic Scleroderma Treatment Market, by Calcium Channel Blockers, by Region, 2016-2028 (USD Million)
    5.8.1.

Worldwide Systemic Scleroderma Treatment Industry to 2028 - by Drug Class, Regions & Segment Forecast - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 24, 2021
Pharmaceutical, Health, Other Health, Autoimmune diseases, Organ systems, Medical specialties, Mucinoses, Anatomy, Connective tissue diseases, Systemic scleroderma, Scleroderma, Systemic

Global Systemic Scleroderma Treatment Market, by Immuno-suppressors, By Region, 2016-2028 (USD Million)

Key Points: 
  • Global Systemic Scleroderma Treatment Market, by Immuno-suppressors, By Region, 2016-2028 (USD Million)
    5.4.1.
  • Global Systemic Scleroderma Treatment Market, by Phosphodiesterase 5 inhibitors-PHA, by Region, 2016-2028 (USD Million)
    5.5.1.
  • Global Systemic Scleroderma Treatment Market, by Prostacyclin Analogues, by Region, 2016-2028 (USD Million)
    5.7.1.
  • Global Systemic Scleroderma Treatment Market, by Calcium Channel Blockers, by Region, 2016-2028 (USD Million)
    5.8.1.

United States Scleroderma Market and Competitive Landscape Report 2021: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 3, 2021
Pharmaceutical, Health, Other Health, Autoimmune diseases, Organ systems, Mucinoses, Scleroderma, Medical specialties, Market share, Market analysis, Business, Market

The "US Scleroderma Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Scleroderma Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering.
  • US Scleroderma Market and Competitive Landscape Highlights - 2021, provides comprehensive insights into Scleroderma pipeline products, Scleroderma epidemiology, Scleroderma market valuations and forecast, Scleroderma drugs sales and competitive landscape in the US.
  • The research is classified into seven sections - Scleroderma treatment options, pipeline products, market analysis comprising of epidemiology, key products marketed, market valuations and forecast, drugs sales and market shares.
  • Find out how the market advanced from 2017 and forecast to 2026
    Evaluate commercial market opportunity assessment, positioning, and segmentation for Scleroderma products

Managing Scleroderma Takes a Team - and Your Dermatologist is a Key Player

Retrieved on: 
Wednesday, February 3, 2021
Autoimmune diseases, Organ systems, Medical specialties, Mucinoses, Clinical medicine, Connective tissue diseases, Systemic scleroderma, Scleroderma, Systemic, Scleromyositis

CHADDS FORD, Pa., Feb. 3, 2021 /PRNewswire-PRWeb/ --"'Scleroderma,'" notes dermatologist Dr. Allison Britt Kimmins , "presents as hardening of the skin.'

Key Points: 
  • CHADDS FORD, Pa., Feb. 3, 2021 /PRNewswire-PRWeb/ --"'Scleroderma,'" notes dermatologist Dr. Allison Britt Kimmins , "presents as hardening of the skin.'
  • The nonprofit Scleroderma Foundation reports that about 300,000 people in the United States contend with this difficult and sometimes debilitating condition.
  • However, if the condition is systemic, the overproduction also takes place internally, affecting organs, tightening them and limiting their function."
  • Race may be a factor in the type of scleroderma seen: African Americans have higher rates of systemic scleroderma: Women are affected more than men.